Angion Biomedica Corp. announced the appointment of Ms. Jennifer J. Rhodes as Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary. Additionally, Allen R. Nissenson, M.D., Gilbert S. Omenn, M.D., Ph.D., and Karen J. Wilson have joined the Company’s Board of Directors. Prior to joining Angion, Ms. Rhodes served as General Counsel and Corporate Secretary for Adamas Pharmaceuticals Inc. She also held the roles of Chief Compliance Officer and Chief Business Officer during her time there. Prior to this, Ms. Rhodes held roles as General Counsel, Corporate Secretary, and Chief Compliance Officer at Medivation Inc. Dr. Nissenson is currently an Emeritus Professor of Medicine at the David Geffen School of Medicine at University California Los Angeles, where he previously served as Director of the Dialysis Program and Associate Dean. Dr. Nissenson also holds the position of Emeritus Chief Medical Officer of DaVita Kidney Care. Dr. Omenn is currently the Harold T. Shapiro Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health at the University of Michigan. Earlier, he was the Dean of the School of Public Health and Community Medicine and Professor of Medicine at the University of Washington. Karen J. Wilson is currently the Senior Vice President of Finance at Jazz Pharmaceuticals plc, a biopharmaceutical company, which she joined in 2011. Angion also announced the departure of Michael Yamin from its Board of Directors. He will remain involved with the company in a consulting role.